(Q34479140)

English

Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

0 references

author name string

Russell A

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Haraoui B

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Keystone E

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Klinkhoff A

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1824-38; discussion 1791

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Rheumatic diseases in North America's indigenous peoples

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative toxicity of non-steroidal anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The costs of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The underestimated long term medical and economic consequences of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: safety of infliximab in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The economic impact of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

54-week results on infliximab attract attention at EULAR. European League against Rheumatism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980079-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(00)80079-X

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34479140&oldid=2037286379"